I believe it was said correctly they will do the work and get to the bottom of this unprecedented event in short order. I believe there will be a silver lining in all of this and this may serve to accelerate progress in other areas that are more relevant to where the future of Cancer treatment lies. The share price will be above a dollar in less then 6 months and as a result of progress and deals will move quickly from there. Avid alone will be generating close to 100 million in revenues in short order, we need to stop dragging the past forward....The times they are a changing IMO
I'm looking forward to the coming days, weeks, and months to see how this plays out.
days: NASDAQ Letter weeks: probably nothing months: - CA ending - Q/CC for FY Q4 (last without Avid II revenue) - what happened EXACTLY with SUNRISE Control Arm - statement on 'decided' strategy & path for Bavituximab - start of NEW clinical trials (probably Durvalumab+Bavi is MANY solid Tumours
Results from MSK, and later NCCN will NOT be provided first by PPHM but by the the people that ran the trials.
Before the next Annual Meeting, IMO, we will have done a serious recovery of the situation, know where we go and have initial results already (those OTHER read-outs SK was talking about).
The surprises may come out of what is done with the SUNRISE data. Either sufficiently strong to combine with salvaged PII data that is now available (and is MORE valuable then the PII data PPHM took to the EOPII meeting with the FDA and which the FDA apparently found already sufficient good to allow a PIII) to file a BLA based on 154 patients and the pre-define contingency measures PPHM has build into the SUNRISE protocol (approved by the FDA) to deal with involvement of drugs like Opdivo as 3rd ln treatments affecting SUNRISE
...or...
maybe they file for a BLA chemo+bavi for which the control arm data can be IGNORED (proper to data used in BLA filing is that it may be pre-clinical, PI, PII, PIII as long as there is no PIII clinical trial enrolling - study must be open - and that BTD data does NOT require any comparative arm but must show promise compared to the current treatment). With SUNRISE stopped this is a possibility.
We will know all this before the Annual IMO, while PPHM keeps doing two other things: - extend Avid - put more steam on Immuno-Oncology because it is the future and they are well placed with MSK, NCCN and AstraZeneca to score big time in that market.
So your days, weeks, mounts expectation will probably be a GRADUAL thing spread over about 1 year (A LOST YEAR) and will IMO not be a sudden Black & White event catapulting the PPS into the sky. For now the PPS is artificially kept in a range and there is a reason. Large short positions build up the past weeks (remember on average 40% shorting in PPHM since SUNRISE) will possibly expect big sell volume when the NASDAQ letter arrives and try to tap into it to close (if we let them :). There are trading strategies the only do that, short into such news and close the same day. Overnight shorts (those reported in the SI) know that and use the initial trading short volume to close and then it is no longer THEIR problem but becomes the problem of the traders to fight with the PPHM market makers.
Market Data 
Markets 
AI
